BAY59-7939
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for BAY59-7939, covering 2012-06-13 to 2023-09-07. Get the full timeline:
Most recent: Clinical Trial Update: Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT) [Phase 2]